175 related articles for article (PubMed ID: 38225233)
61. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
62. Enhanced expression of a new class of liver-enriched b-Zip transcription factors, hepatocarcinogenesis-related transcription factor, in hepatocellular carcinomas of rats and humans.
Kishimoto T; Kokura K; Ohkawa N; Makino Y; Yoshida M; Hirohashi S; Niwa S; Muramatsu M; Tamura T
Cell Growth Differ; 1998 Apr; 9(4):337-44. PubMed ID: 9563853
[TBL] [Abstract][Full Text] [Related]
63. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
64. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
65. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.
Zhong M; Zhong C; Cui W; Wang G; Zheng G; Li L; Zhang J; Ren R; Gao H; Wang T; Li X; Che J; Gohda E
BMC Cancer; 2019 May; 19(1):439. PubMed ID: 31088527
[TBL] [Abstract][Full Text] [Related]
66. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
J Hepatol; 2022 Jan; 76(1):123-134. PubMed ID: 34464659
[TBL] [Abstract][Full Text] [Related]
67. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
[TBL] [Abstract][Full Text] [Related]
68. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles.
Seo W; Gao Y; He Y; Sun J; Xu H; Feng D; Park SH; Cho YE; Guillot A; Ren T; Wu R; Wang J; Kim SJ; Hwang S; Liangpunsakul S; Yang Y; Niu J; Gao B
J Hepatol; 2019 Nov; 71(5):1000-1011. PubMed ID: 31279903
[TBL] [Abstract][Full Text] [Related]
69. Overexpression of GRIM-19, a mitochondrial respiratory chain complex I protein, suppresses hepatocellular carcinoma growth.
Kong D; Zhao L; Du Y; He P; Zou Y; Yang L; Sun L; Wang H; Xu D; Meng X; Sun X
Int J Clin Exp Pathol; 2014; 7(11):7497-507. PubMed ID: 25550785
[TBL] [Abstract][Full Text] [Related]
70. PDCD6 Promotes Hepatocellular Carcinoma Cell Proliferation and Metastasis through the AKT/GSK3β/β-catenin Pathway.
Wen SY; Liu YT; Wei BY; Ma JQ; Chen YY
Biomed Environ Sci; 2023 Mar; 36(3):241-252. PubMed ID: 37005078
[TBL] [Abstract][Full Text] [Related]
71. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.
Moon H; Park H; Chae MJ; Choi HJ; Kim DY; Ro SW
BMC Cancer; 2022 Apr; 22(1):423. PubMed ID: 35439973
[TBL] [Abstract][Full Text] [Related]
72. TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway.
Wang L; Chen C; Feng S; Tian J
Mol Med Rep; 2018 May; 17(5):7017-7026. PubMed ID: 29568863
[TBL] [Abstract][Full Text] [Related]
73. The transcription factor c-Jun protects against liver damage following activated β-Catenin signaling.
Trierweiler C; Blum HE; Hasselblatt P
PLoS One; 2012; 7(7):e40638. PubMed ID: 22792392
[TBL] [Abstract][Full Text] [Related]
74. Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans.
Zhang S; Wang J; Wang H; Fan L; Fan B; Zeng B; Tao J; Li X; Che L; Cigliano A; Ribback S; Dombrowski F; Chen B; Cong W; Wei L; Calvisi DF; Chen X
Am J Pathol; 2018 Apr; 188(4):995-1006. PubMed ID: 29378174
[TBL] [Abstract][Full Text] [Related]
75. LncRNA LL22NC03-N14H11.1 promoted hepatocellular carcinoma progression through activating MAPK pathway to induce mitochondrial fission.
Yi T; Luo H; Qin F; Jiang Q; He S; Wang T; Su J; Song S; Qin X; Qin Y; Zhou X; Huang Z
Cell Death Dis; 2020 Oct; 11(10):832. PubMed ID: 33028809
[TBL] [Abstract][Full Text] [Related]
76. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance.
Feng DY; Zheng H; Tan Y; Cheng RX
World J Gastroenterol; 2001 Feb; 7(1):33-6. PubMed ID: 11819729
[TBL] [Abstract][Full Text] [Related]
77. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
Esparza-Baquer A; Labiano I; Sharif O; Agirre-Lizaso A; Oakley F; Rodrigues PM; Zhuravleva E; O'Rourke CJ; Hijona E; Jimenez-Agüero R; Riaño I; Landa A; La Casta A; Zaki MYW; Munoz-Garrido P; Azkargorta M; Elortza F; Vogel A; Schabbauer G; Aspichueta P; Andersen JB; Knapp S; Mann DA; Bujanda L; Banales JM; Perugorria MJ
Gut; 2021 Jul; 70(7):1345-1361. PubMed ID: 32907830
[TBL] [Abstract][Full Text] [Related]
78. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
[TBL] [Abstract][Full Text] [Related]
79. STAT3 and AKT signaling pathways mediate oncogenic role of NRSF in hepatocellular carcinoma.
Ma M; Zhou Y; Sun R; Shi J; Tan Y; Yang H; Zhang M; Shen R; Xu L; Wang Z; Fei J
Acta Biochim Biophys Sin (Shanghai); 2020 Oct; 52(10):1063-1070. PubMed ID: 32556117
[TBL] [Abstract][Full Text] [Related]
80. Carboxypeptidase A6 Promotes the Proliferation and Migration of Hepatocellular Carcinoma by Up-regulating AKT Signaling Pathway.
Huang QB; Zhang HW; Liao ZB
Curr Med Sci; 2019 Oct; 39(5):727-733. PubMed ID: 31612389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
